Solesence Inc

SLSN

Market cap $94.6M

Global Award Recognizes Excellence in Service, Reliability, and Innovation ROMEOVILLE, Ill., June 18, 2026 (GLOBE NEWSWIRE) -- Solésence, Inc.

SPF-Infused Concealer Featuring Kleair™, WHSPR™, and Chromalüm™ Recognized Across Anti-Aging, Color Cosmetics, and Compromised Skin

Solesence incurs a Q1 loss per share as shipment delays pressure revenues, even as gross margin improves and the company reaffirms its 2026 profitability targets.

The report, led by the United Kingdom's APPG for Beauty, Hair & Wellbeing, calls for a national strategy to combat UV exposure, including Government support to enable access to adequate protection, build public awareness and combat misinformation.

Solesence, Inc. (SLSN) Q1 2026 Earnings Call Transcript

Advances implementation of Transform and Transcend strategic initiative across Operational Excellence and New Technology Commercialization ROMEOVILLE, Ill., May 12, 2026 (GLOBE NEWSWIRE) -- Solésence, Inc. (Nasdaq: SLSN), a leader in scientifically-driven health care solutions across beauty and life science categories, today announced financial results for the first quarter ended March 31, 2026.

New platform technologies enable OTC-grade sensitive skin claims in previously inaccessible anhydrous formats and bring environmental protection deeper into the color cosmetics assortment

ROMEOVILLE, Ill., April 28, 2026 (GLOBE NEWSWIRE) -- Solésence, Inc. (Nasdaq: SLSN), a leader in scientifically-driven health care solutions across beauty and life science categories, today announced that the Company will report results for the first quarter of 2026 after the market opens on Tuesday, May 12, 2026, and host a conference call and webcast on the same date.

Marc James to Join Board of Directors and Serve on Audit, Compensation, and Nominating Committees ROMEOVILLE, Ill., April 27, 2026 (GLOBE NEWSWIRE) -- Solésence, Inc. (Nasdaq: SLSN), a leader in scientifically-driven health care solutions across beauty and life science categories, today announced the appointment of Marc James to its Board of Directors as an independent director, effective immediately.

Discover why Zacks issues an "Underperform" rating for Solesence, being the first on Wall Street to initiate coverage on the stock. Learn how margin pressure, cash flow weakness, rising leverage and execution challenges are weighing on growth.